Uncategorized
Speaker: Gene therapy well-suited for retinal disease treatment
LAS VEGAS — Safety results in the phase 2a trial of AVA-101 support ocular gene therapy as a potential long-term treatment option for wet age-related macular degeneration, according to a presentation here. There is, however, still a need for anti-VEGF rescue therapy. Jeffrey S. Heier, MD, related topline results from the phase 1 and 2a clinical trials of AVA-101 (Avalanche Biotechnologies) at Retina Subspecialty Day preceding the American Academy of Ophthalmology annual meeting.